IE
OKUR

Israel Englander’s OnKure Therapeutics OKUR Stock Holding History

Israel Englander’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,499
Closed -$126K – 6513
2026
Q1 		$126K Buy
+30,499
New +$94.2K ﹤0.01% 5302
2025
Q1 		– Sell
-144,099
Closed -$1.24M – 6536
2024
Q4 		$1.24M Buy
144,099
+132,042
+1,095% +$2M ﹤0.01% 4024
2024
Q3 		$205K Buy
12,057
+1,058
+10% +$15.7K ﹤0.01% 5437
2024
Q2 		$166K Buy
+10,999
New +$186K ﹤0.01% 5203
2024
Q1 		– Sell
-15,889
Closed -$254K – 6745
2023
Q4 		$254K Buy
15,889
+3,620
+30% +$226K ﹤0.01% 5052
2023
Q3 		$934K Buy
+12,269
New +$834K ﹤0.01% 4234
2023
Q2 		– Sell
-2,394
Closed -$143K – 6793
2023
Q1 		$143K Sell
2,394
-912
-28% -$33K ﹤0.01% 5297
2022
Q4 		$77K Sell
3,306
-437
-12% -$11.6K ﹤0.01% 5658
2022
Q3 		$125K Sell
3,743
-2,226
-37% -$73.1K ﹤0.01% 5885
2022
Q2 		$158K Buy
+5,969
New +$139K ﹤0.01% 5750
2022
Q1 		– Sell
-2,499
Closed -$214K – 7601
2021
Q4 		$214K Buy
+2,499
New +$184K ﹤0.01% 5853

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's OKUR Position: Q2 2026 in Review

Israel Englander sold out of OnKure Therapeutics (OKUR) in Q2 2026, closing a stake of 30,499 shares — an estimated $126K sold.

Israel Englander first reported a position in OKUR in Q4 2021 and held it in 11 quarters. The position peaked at $1.24M in Q4 2024. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Israel Englander reported no remaining OnKure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 30,499 OnKure Therapeutics shares in Q2 2026, an estimated $126K.
  • Israel Englander first reported a position in OnKure Therapeutics in Q4 2021 and held it in 11 quarters.
  • Israel Englander's OnKure Therapeutics position peaked at $1.24M in Q4 2024.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.